MAPT and Alzheimer disease: Subsets of participants with available multishell dMRI data and CSF biomarkers of AD pathology were used to compare the performance of ADIC-NODDI, Aβ42/40, tau and ptau181 in differentiating CN and CI trajectories and predicting cognitive decline.